Umicore’s Active Pharmaceutical Ingredients facility in Pilar, Buenos Aires, successfully passed its second cGMP audit by the US Food and Drug Administration. The Auditor acknowledged that both the production area and the associated documentation were well maintained, rewarding Umicore’s constant focus on the quality of its production processes and systems. Umicore manufactures in Pilar cisplatin, carboplatin, oxaliplatin and arsenic trioxide: four oncology APIs produced for global markets...